compani
still high qualiti hold
highest-qu
eli lilli report good set result week sale beat
consensu core ep beat despit weaker-than-
expect gross margin full-year core ep guidanc upgrad
midpoint compani announc result well-flag
strateg review futur anim health busi elanco elanco
list year portion share offer
rest stake divest next year pleas
sharehold past three year lilli stori
improv enviabl execut
commercialis key product
although without
disappoint along way continu believ lilli
increasingli reflect share price see lull excit launch
next month withstand view anti-cgrp
drug big class new gener pipelin asset brought
forward downgrad hold reduc price target slightli
lilli sale growth built solid proposit trulic lilli
headwind form legaci product notabl patent expiri
ciali grown revenu strongli thank diabet product
trulic agonist think big drug
rais forecast slightli class may face price
pressur year come alreadi factor
slightli ahead consensu next four year think trulic
continu perform volum basi becom
pessimist although backdrop expect
high
new pipelin asset need start shine success
lilli ra drug olumi underwhelm verzenio breast cancer
formid opposit form incumb class
ibranc lilli process re-stock late-stag pipelin
intern via deal note interest asset form
pegilodecakin earli data sever tumour type
came armo bioscienc acquisit earlier year
yet know address market could ultim
lilli trade premium peer core earn lilli share
expens large-cap sector averag given
profil growth offer think deserv repres
reason full valuat
chang made note
compani
perform rel
compani base us
global biopharmaceut
profit loss summari
growth margin
period patent expiri fall net incom lilli
return top-lin growth
key driver lilli futur growth rejuven diabet
franchis complet product portfolio previous
includ basal insulin offer class
believ lilli nearli doubl revenu
diabet
second driver rich late-stag pipelin
potenti deliv three blockbust drug area
psoriasi headach oncolog
margin also improv lilli invest start
pay term revenu
valuat dcf-deriv
chang net debt
average cost debt
risk invest thesi
pipelin might deliv potenti blockbust drug
identifi might either fail reach market fail
gain traction
diabet franchis might threaten competitor product
space sooner
compani
collabor
collabor
collabor
collabor
compani
profit loss account
sale
 revenu
 revenu
incom tax
incom tax
incom tax
incom tax
compani
account receiv net allow
pre-paid expens
goodwil intang net
total asset
total asset
total asset
total asset
properti equip net
short-term borrow current matur long-term debt
total liabilit
total liabilit
total liabilit
total liabilit
sharehold equiti
total liabil equiti
total liabil equiti
total liabil equiti
total liabil equiti
compani
net cash provid oper activ
net cash provid oper activ
net cash provid oper activ
net cash provid oper activ
addit dispos properti equip net
chang short term invest net
chang non-current invest net
purchas product right
purchas in-process
paid acquisit net cash acquir
net cash use invest activ
net cash use invest activ
net cash use invest activ
net cash use invest activ
net chang short-term borrow
proce issuanc long-term debt
repay long-term debt
puchas common stock
net cash use financ activ
net cash use financ activ
net cash use financ activ
net cash use financ activ
fx effect cash equival
 cash equival begin year
 cash equival end year
 cash equival end year
 cash equival end year
 cash equival end year
compani
pleas note use research report subject condit restrict set forth gener inv
pleas note use research report subject condit restrict set forth gener invest
pleas note use research report subject condit restrict set forth gener inv
pleas note use research report subject condit restrict set forth gener inv
disclosur legal disclaim end document
